Structure Therapeutics Inc (GPCR)

$41.23 +0.85 (2.10%)
Market Cap 2.81B
Revenue (ttm) 0.00
Net Income (ttm) -141.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,562,300
Avg Vol 735,084
Day's Range N/A - N/A
Shares Out 69.62M
Stochastic %K 10%
Beta -1.45
Analysts Strong Sell
Price Target $106.73

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
Theflash88
Theflash88 Sep. 9 at 5:23 PM
$GPCR
0 · Reply
Twitgb
Twitgb Sep. 9 at 5:19 PM
$GPCR so rollercoaster is not over, this is brutal. lot of patience and good decisions for all, guys its not much but i rooting for you longs.
0 · Reply
DG20
DG20 Sep. 9 at 2:58 PM
$VKTX $NVO is the worlds largest pharmaceutical peptide developer and repeatedly the CEO has stated over the past year he is looking for a synergistic company to partner with or purchase to regain lost GLP market share. There is no way to know if it’s $KLRA or $VKTX as they are the two best late stage options but it’s almost certainly not going to be a small molecule developer like $GPCR as small molecules are not Novo’s strong suit…
2 · Reply
blocktrade
blocktrade Sep. 9 at 2:14 PM
$GPCR nice sell yesterday. 🤡🤡🤡🤡
0 · Reply
Twitgb
Twitgb Sep. 9 at 2:06 PM
$GPCR well, congrats for the strong hands, it was a rollercoaster. Im just an outsider but rooting for you.
0 · Reply
Bbbb44444
Bbbb44444 Sep. 9 at 1:56 PM
$GPCR easy money after that drop yesterday
1 · Reply
prismmarketview
prismmarketview Sep. 9 at 11:50 AM
A mixed Tuesday: 15 of 27 PRISM indexes closed lower in a session marked by sharp single-stock moves. Space (+3.74%), AI datacenter (+3.04%) and crypto mining (+2.79%) led the gainers, while global health (-5.89%) and pet care (-5.02%) lagged. Biggest single-stock moves: $PDSB +36.36% and +19.42% led the gainers, while $BIAF -41.52%, $JAGX -30.60% and $GPCR -14.70% led the decliners. Full board below. Index detail at http://prismmarketview.com
0 · Reply
Arcides
Arcides Sep. 9 at 3:23 AM
$GPCR mama mia, this had the 5th highest daily volume in a year on this red day...a lot, a lot of volume.
0 · Reply
wall_street13
wall_street13 Sep. 9 at 2:31 AM
$GPCR worth a trade here... end of the year will see a flurry of m&a.
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz Sep. 9 at 12:45 AM
$GPCR for aleniglipron it look good but like nausea and other issues. Oral glp-1 looks good but maybe market expecting more than only a 2 % weight loss difference improvement imo
0 · Reply
Latest News on GPCR
Structure weakness ‘disconnected’ from underlying data, says Jefferies

2026-09-08T20:00:15.000Z - 1 day ago

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure obesity portfolio updates ‘encouraging,’ says Clear Street

2026-09-08T16:20:54.000Z - 1 day ago

Structure obesity portfolio updates ‘encouraging,’ says Clear Street

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

2026-09-08T12:36:47.000Z - 1 day ago

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Structure Therapeutics Transcript: Study result

Sep 8, 2026, 8:30 AM EDT - 1 day ago

Structure Therapeutics Transcript: Study result

Structure Therapeutics Press release: Study result

Sep 8, 2026, 8:30 AM EDT - 1 day ago

Structure Therapeutics Press release: Study result

Structure Therapeutics Slides: Study result

Sep 8, 2026, 8:30 AM EDT - 1 day ago

Structure Therapeutics Slides: Study result

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Sep 8, 2026, 8:00 AM EDT - 1 day ago

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Sep 3, 2026, 7:30 AM EDT - 6 days ago

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Structure Therapeutics price target raised to $111 from $101 at Canaccord

2026-08-07T11:30:54.000Z - 4 weeks ago

Structure Therapeutics price target raised to $111 from $101 at Canaccord

Structure Therapeutics price target lowered to $97 from $100 at Citi

2026-08-07T10:45:22.000Z - 4 weeks ago

Structure Therapeutics price target lowered to $97 from $100 at Citi

Structure Therapeutics price target lowered to $110 from $113 at Citizens

2026-08-07T10:16:46.000Z - 4 weeks ago

Structure Therapeutics price target lowered to $110 from $113 at Citizens

Structure Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 4:00 PM EDT - 4 weeks ago

Structure Therapeutics Earnings release: Q2 2026

Structure Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 4:00 PM EDT - 4 weeks ago

Structure Therapeutics Quarterly report: Q2 2026

Structure Therapeutics Transcript: AGM 2026

Jun 17, 2026, 12:00 PM EDT - 2 months ago

Structure Therapeutics Transcript: AGM 2026

The Next Phase Of The Obesity Drug Race

Jun 13, 2026, 2:00 PM EDT - 2 months ago

The Next Phase Of The Obesity Drug Race

LLY NVO

Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright

2026-06-11T10:06:10.000Z - 3 months ago

Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright

Structure Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 3 months ago

Structure Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Structure's experimental obesity pill shows no signs of liver injury

Jun 5, 2026, 5:16 PM EDT - 3 months ago

Structure's experimental obesity pill shows no signs of liver injury

Structure Therapeutics announces ACCESS trial data published in Nature Medicine

2026-06-05T20:10:53.000Z - 3 months ago

Structure Therapeutics announces ACCESS trial data published in Nature Medicine

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Jun 5, 2026, 4:05 PM EDT - 3 months ago

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics Slides: Corporate presentation

Jun 5, 2026, 7:00 AM EDT - 3 months ago

Structure Therapeutics Slides: Corporate presentation

Structure Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 3 months ago

Structure Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

May 26, 2026, 4:05 PM EDT - 3 months ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 4:05 PM EDT - 4 months ago

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 4 months ago

Structure Therapeutics Earnings release: Q1 2026

Structure Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 4 months ago

Structure Therapeutics Quarterly report: Q1 2026

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Apr 27, 2026, 4:05 PM EDT - 4 months ago

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Canaccord starts Structure Therapeutics on oral weight loss pipeline

2026-04-27T12:58:41.000Z - 4 months ago

Canaccord starts Structure Therapeutics on oral weight loss pipeline

Structure Therapeutics initiated with a Buy at Canaccord

2026-04-27T10:00:27.000Z - 4 months ago

Structure Therapeutics initiated with a Buy at Canaccord

Structure Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Structure Therapeutics Proxy statement: Proxy filing

Structure Therapeutics appoints Matthew Lang as COO

2026-04-14T20:17:51.000Z - 4 months ago

Structure Therapeutics appoints Matthew Lang as COO

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Apr 14, 2026, 4:05 PM EDT - 4 months ago

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

2026-03-16T15:55:34.000Z - 5 months ago

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

2026-03-16T15:10:26.000Z - 5 months ago

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

LLY NVO

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Mar 16, 2026, 10:46 AM EDT - 5 months ago

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Structure Therapeutics Transcript: Study result

Mar 16, 2026, 8:30 AM EDT - 5 months ago

Structure Therapeutics Transcript: Study result

Structure Therapeutics Press release: Study result

Mar 16, 2026, 8:30 AM EDT - 5 months ago

Structure Therapeutics Press release: Study result

Structure Therapeutics Slides: Study result

Mar 16, 2026, 8:30 AM EDT - 5 months ago

Structure Therapeutics Slides: Study result

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

2026-03-16T11:22:17.000Z - 5 months ago

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

2026-03-02T11:26:56.000Z - 6 months ago

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

Structure Therapeutics price target lowered to $113 from $120 at Citizens

2026-02-27T10:55:51.000Z - 6 months ago

Structure Therapeutics price target lowered to $113 from $120 at Citizens

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Feb 26, 2026, 4:02 PM EST - 6 months ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:00 PM EST - 6 months ago

Structure Therapeutics Annual report: Q4 2025

Structure Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:00 PM EST - 6 months ago

Structure Therapeutics Earnings release: Q4 2025

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 7 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

2026-01-30T15:51:54.000Z - 7 months ago

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

2026-01-22T11:51:35.000Z - 7 months ago

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 21, 2026, 10:05 AM EST - 7 months ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 7 months ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Structure Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Structure Therapeutics Slides: Corporate presentation

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 9 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 9 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 9 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 9 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure Therapeutics Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 9 months ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Dec 8, 2025, 8:30 AM EST - 9 months ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Dec 8, 2025, 8:30 AM EST - 9 months ago

Structure Therapeutics Slides: Study Update

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 9 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 9 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 9 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 10 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 10 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Structure Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Structure Therapeutics Quarterly report: Q3 2025

Structure Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Structure Therapeutics Earnings release: Q3 2025

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 10 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:45 AM EDT - 12 months ago

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 1 year ago

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 1 year ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Structure Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Quarterly report: Q2 2025

Structure Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Earnings release: Q2 2025

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 1 year ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 1 year ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Structure Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Earnings release: Q1 2025

Structure Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Quarterly report: Q1 2025

Structure Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Structure Therapeutics Proxy statement: Proxy Filing

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:00 PM EDT - 1 year ago

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Structure Therapeutics Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Annual report: Q4 2024

Structure Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q4 2024

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 10:30 AM EST - 1 year ago

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Transcript: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Transcript: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Quarterly report: Q3 2024

Structure Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q3 2024

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 9:10 AM EDT - 1 year ago

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 10:00 AM EDT - 2 years ago

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 2 years ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 2 years ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q2 2024

Structure Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q2 2024

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 2 years ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 2 years ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 2 years ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 2 years ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 2 years ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 2 years ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Transcript: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Registration statement: Registration Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Registration statement: Registration Filing

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Structure Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q1 2024

Structure Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q1 2024

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 2 years ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Structure Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Proxy statement: Proxy Filing

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 2 years ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Theflash88
Theflash88 Sep. 9 at 5:23 PM
$GPCR
0 · Reply
Twitgb
Twitgb Sep. 9 at 5:19 PM
$GPCR so rollercoaster is not over, this is brutal. lot of patience and good decisions for all, guys its not much but i rooting for you longs.
0 · Reply
DG20
DG20 Sep. 9 at 2:58 PM
$VKTX $NVO is the worlds largest pharmaceutical peptide developer and repeatedly the CEO has stated over the past year he is looking for a synergistic company to partner with or purchase to regain lost GLP market share. There is no way to know if it’s $KLRA or $VKTX as they are the two best late stage options but it’s almost certainly not going to be a small molecule developer like $GPCR as small molecules are not Novo’s strong suit…
2 · Reply
blocktrade
blocktrade Sep. 9 at 2:14 PM
$GPCR nice sell yesterday. 🤡🤡🤡🤡
0 · Reply
Twitgb
Twitgb Sep. 9 at 2:06 PM
$GPCR well, congrats for the strong hands, it was a rollercoaster. Im just an outsider but rooting for you.
0 · Reply
Bbbb44444
Bbbb44444 Sep. 9 at 1:56 PM
$GPCR easy money after that drop yesterday
1 · Reply
prismmarketview
prismmarketview Sep. 9 at 11:50 AM
A mixed Tuesday: 15 of 27 PRISM indexes closed lower in a session marked by sharp single-stock moves. Space (+3.74%), AI datacenter (+3.04%) and crypto mining (+2.79%) led the gainers, while global health (-5.89%) and pet care (-5.02%) lagged. Biggest single-stock moves: $PDSB +36.36% and +19.42% led the gainers, while $BIAF -41.52%, $JAGX -30.60% and $GPCR -14.70% led the decliners. Full board below. Index detail at http://prismmarketview.com
0 · Reply
Arcides
Arcides Sep. 9 at 3:23 AM
$GPCR mama mia, this had the 5th highest daily volume in a year on this red day...a lot, a lot of volume.
0 · Reply
wall_street13
wall_street13 Sep. 9 at 2:31 AM
$GPCR worth a trade here... end of the year will see a flurry of m&a.
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz Sep. 9 at 12:45 AM
$GPCR for aleniglipron it look good but like nausea and other issues. Oral glp-1 looks good but maybe market expecting more than only a 2 % weight loss difference improvement imo
0 · Reply
IM11
IM11 Sep. 8 at 10:20 PM
$GPCR Looks to be recovering a little after hours but today was painful. I am trying to figure out what in their dataset investors didn't like? Here are the only 'negatives' that I saw and compared to the competition 'Foundayo and Oral Wegovy', every aspect looked like Best In Class. 1. For the world's only Amylin small molecule human SAD data (2671), I think where they screwed up was showing ANY efficacy data. The test was on non-obese patients, so they shouldn't expect much weight loss in <30 days. But the 3% on the highest 10 mg dose which had tolerability issues, I think is what the market didn't like about the Amylin announcement even though GPCR just proved to be the only company in the world to be capable of developing a safe small molecule amylin pill. 2. For Aleniglipron (1290), I assume that what the street didn't like was the fact that it showed some level of plateauing, partly due to the fact that many of the patients weren't on the 180 mg dose for very long. Thoughts?
0 · Reply
SkylineBlueAnalytics
SkylineBlueAnalytics Sep. 8 at 9:02 PM
$GPCR $NVO $VKTX. They don’t take account of dilutions and general sell off. We have 99% bios with price of $5 and target of $100 not changing until BK or stop of coverage also: Piper Sandler acts as a sales agent alongside Cantor Fitzgerald for Viking Therapeutics (NASDAQ: VKTX) under an At-The-Market (ATM) equity offering sales agreement. They are not fiduciary for you. It is in their best interest to give high PT…
0 · Reply
Wallst45
Wallst45 Sep. 8 at 8:42 PM
$GPCR what a dump lol 😂
0 · Reply
nlrmandate
nlrmandate Sep. 8 at 8:10 PM
$GPCR $VKTX anyone have any idea why Structure held at <8% until the last hour or so and then dropped to a total of 14%+? Usually when a trial drops it, the drip happens all at once. With Structure today, it creeped down to about 8-9% the dropped an additional 6% in the last hour. And now, AH, it's up a percent. Seems like the market didn't quite know what to do with its results?
2 · Reply
AStrokeOfLuck
AStrokeOfLuck Sep. 8 at 7:58 PM
$GPCR
0 · Reply
Twitgb
Twitgb Sep. 8 at 7:06 PM
$VKTX $GPCR is a massacre today, im sorry for them. Except kyle, karma is a bitch. This kind of days.... Maybe tomorrow all goes back where it was before.
2 · Reply
Jten10
Jten10 Sep. 8 at 6:59 PM
$GPCR This should be down 20%+. Data is terrible and, once again, small molecules are shown to just not be in the same league as dual agonist peptide therapies. Will be very interesting to contrast $VKTX impending data release with this disappointment.
1 · Reply
notreload_ai
notreload_ai Sep. 8 at 6:55 PM
$GPCR posted encouraging aleniglipron and amylin results, but Phase 3 is still years away, GI side effects emerged at active amylin doses, and the bar for oral GLP-1 drugs is already high. https://notreload.xyz/xy/positive-obesity-data-sell-the-news-reaction-for-gpcr/
0 · Reply
biolover
biolover Sep. 8 at 6:36 PM
$VKTX there is low volume sale in $GPCR Hard for bio funds to give up on an idea. Struture mgt is trying but coming up with small molecule inh if GPCR bid not easy. Pfizer tried that.
1 · Reply
Quantumup
Quantumup Sep. 8 at 5:29 PM
BRiley reiterated $VKTX Buy-$85 $GPCR $LLY NVO MBX KLRA Here's what BRiley said in its note to investors: https://x.com/Quantumup1/status/2097376247701504397?s=20
1 · Reply
DG20
DG20 Sep. 8 at 3:50 PM
$GPCR $VKTX Sell the news is a real phenomenon in biotech unless your data crushes. Sadly, the same risk is present with Vikings maintenance trial. The ph3 read through especially for the 21 week data is markedly important…
2 · Reply
Bbbb44444
Bbbb44444 Sep. 8 at 3:31 PM
$GPCR Lol. Positive data and timber!
1 · Reply